Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2897247rdf:typepubmed:Citationlld:pubmed
pubmed-article:2897247lifeskim:mentionsumls-concept:C0018282lld:lifeskim
pubmed-article:2897247lifeskim:mentionsumls-concept:C0040690lld:lifeskim
pubmed-article:2897247lifeskim:mentionsumls-concept:C2246476lld:lifeskim
pubmed-article:2897247pubmed:issue1lld:pubmed
pubmed-article:2897247pubmed:dateCreated1988-7-7lld:pubmed
pubmed-article:2897247pubmed:abstractTextThe effects of two forms of transforming growth factor-beta, TGF-beta 1 and TGF-beta 2, upon the proliferative response of murine thymocytes were investigated in this study. TGF-beta 1 and TGF-beta 2 were found to be equipotent growth inhibitors of interleukin-1 (IL-1)- and phytohemagglutinin (PHA)-stimulated thymocytes when added at the initiation of the cultures. These factors suppressed the proliferative response in a dose-dependent fashion between 0.4 and 100 pM. The proliferative response was maximally inhibited (90% inhibition) at 100 pM. The half-maximal inhibitory dose (ID50) was 6 and 4 pM for TGF-beta 1 and TGF-beta 2, respectively. These factors were less effective or ineffective at suppressing the proliferation of thymocytes which had been prestimulated for 24 to 48 hr by IL-1 and PHA. Neither factor inhibited interleukin-2 (IL-2)-dependent thymocyte proliferation or the proliferation of an IL-2-dependent cytotoxic T cell line (CTL-L), suggesting that the anti-proliferative actions of these factors was by inhibition of cellular events triggered by IL-1. Furthermore, anti-TGF-beta 1 antibodies did neutralize the biological actions of TGF-beta 1 and these antibodies did block the binding of 125I-labeled TGF-beta 1 to cell surface receptors showing that the inhibitory action is mediated through specific receptors for TGF-beta 1 on thymocytes. These antibodies, however, did not neutralize the anti-proliferative action of TGF-beta 2. Although TGF-beta 1 and TGF-beta 2 exhibit very similar biological activities, these molecules are antigenically different and, therefore, have different tertiary structures.lld:pubmed
pubmed-article:2897247pubmed:languageenglld:pubmed
pubmed-article:2897247pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2897247pubmed:citationSubsetIMlld:pubmed
pubmed-article:2897247pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2897247pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2897247pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2897247pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2897247pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2897247pubmed:statusMEDLINElld:pubmed
pubmed-article:2897247pubmed:monthJunlld:pubmed
pubmed-article:2897247pubmed:issn0008-8749lld:pubmed
pubmed-article:2897247pubmed:authorpubmed-author:SegariniPPlld:pubmed
pubmed-article:2897247pubmed:authorpubmed-author:EllingsworthL...lld:pubmed
pubmed-article:2897247pubmed:authorpubmed-author:CarrilloPPlld:pubmed
pubmed-article:2897247pubmed:authorpubmed-author:DaschJJlld:pubmed
pubmed-article:2897247pubmed:authorpubmed-author:NakayamaDDlld:pubmed
pubmed-article:2897247pubmed:authorpubmed-author:WaegellWWlld:pubmed
pubmed-article:2897247pubmed:issnTypePrintlld:pubmed
pubmed-article:2897247pubmed:volume114lld:pubmed
pubmed-article:2897247pubmed:ownerNLMlld:pubmed
pubmed-article:2897247pubmed:authorsCompleteYlld:pubmed
pubmed-article:2897247pubmed:pagination41-54lld:pubmed
pubmed-article:2897247pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:meshHeadingpubmed-meshheading:2897247-...lld:pubmed
pubmed-article:2897247pubmed:year1988lld:pubmed
pubmed-article:2897247pubmed:articleTitleTransforming growth factor-beta s are equipotent growth inhibitors of interleukin-1-induced thymocyte proliferation.lld:pubmed
pubmed-article:2897247pubmed:affiliationImmunology Laboratory, Collagen Corporation, Palo Alto, California 94303.lld:pubmed
pubmed-article:2897247pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2897247pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2897247lld:pubmed